GLP-1 diabetes drugs like Ozempic may modestly reduce cancer risks Widely used GLP-1 drugs for type 2 diabetes such as Novo Nordisk's Ozempic may modestly reduce the risk of obesity-related ...

Novo Nordisk has reached the end of its two-year suspension from the Association of the British Pharmaceutical Industry (ABPI) for breaches of its code of practice, after showing "significant and ...

The partnership with Flagship will bring Novo Nordisk into closer contact with the VC's portfolio of 41 biotech companies, with the aim of creating a portfolio of "transformational" medicines for ...

Viking Therapeutics faces tough competition in the obesity drug market dominated by Eli Lilly and Novo Nordisk, with first-mover advantages hard to overcome. VK2735 shows promising early efficacy ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The company said it has long covered GLP-1s for both weight loss and diabetes, but recently added new requirements, including documentation from a medical provider and enrollment in a virtual health .